Biosimilars are reshaping the drug market — but have we reached a true inflection point? Next Thursday, STAT’s Ed Silverman will host a virtual conversation with a panel of experts to dig into what’s changing, including shifts at the FDA, what’s holding the market back, and what comes next.
Last call to RSVP: Tune in live on Sept. 24 at 1 p.m. ET.
Featured Speakers
Chris Brown, managing principal, McAteer
Madelaine Feldman, M.D., FACR, Coalition of Rheumatology Organizations, VP Advocacy & Gov’t Affairs; clinical assistant professor of medicine, Tulane School of Medicine
Michael A. Gonzales, independent healthcare consultant
Ed Silverman, Pharmalot columnist, senior writer, STAT
%20MH%20Testing/Larger%20Header%20Logos/STAT_Events2.png?height=88&upscale=true&name=STAT_Events2.png){kind=small}
.png?width=1200&upscale=true&name=924_Samsung_VirtualEvent_Marketing_EmailTall%20(1).png)
%20MH%20Testing/Footer%20Icons/Flipboard-logo.png?width=60&height=60&upscale=true&name=Flipboard-logo.png){kind=logo}
%20MH%20Testing/Footer%20Icons/X-logo.png?width=60&height=60&upscale=true&name=X-logo.png){kind=logo}
%20MH%20Testing/Footer%20Icons/Linkedin-logo.png?width=60&height=60&upscale=true&name=Linkedin-logo.png){kind=logo}
%20MH%20Testing/Footer%20Icons/Facebook-logo.png?width=60&height=60&upscale=true&name=Facebook-logo.png){kind=logo}
%20MH%20Testing/Footer%20Icons/Youtube-logo.png?width=60&height=60&upscale=true&name=Youtube-logo.png){kind=logo}
%20MH%20Testing/Footer%20Icons/Instagram-logo.png?width=60&height=60&upscale=true&name=Instagram-logo.png){kind=logo}
%20MH%20Testing/Footer%20Icons/Threads-logo.png?width=60&height=60&upscale=true&name=Threads-logo.png){kind=logo}